Human Oncology Push ImpriMed is shifting from veterinary AI driven drug response predictions to human oncology, leveraging its ex vivo drug sensitivity approach and Mayo Clinic Platform Accelerate involvement to pursue joint development, licensing, and pilot collaborations with academic medical centers and pharma partners.

Veterinary Market Expansion The company has broad U.S. deployment and strong demand for personalized canine cancer testing, creating sales opportunities with veterinary clinics, veterinary networks, and pet insurers through direct DRP sales, white label arrangements, or co-branded services.

Financial Momentum A track record of fundraising alongside solid revenue signals market credibility and budget for partnerships with large buyers, enabling concerted outreach to hospitals, research labs, and multinational veterinary groups for multi site programs.

AI Driven Value Its AI based drug response predictions and ex vivo data offer a differentiator for precision oncology; position as an enterprise grade decision support and analytics offering that can integrate with hospital data ecosystems and existing AI or data platforms.

Strategic Partnerships Participation in accelerator programs and major industry events demonstrates a strategy to build ecosystem partnerships; leverage these channels to secure co development deals, sponsored trials, and access to clinical research networks.